Imunon, Inc. (NASDAQ:IMNN) Receives Average Rating of “Hold” from Analysts

Shares of Imunon, Inc. (NASDAQ:IMNN) have earned an average recommendation of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $232.50.

A number of equities research analysts have recently issued reports on IMNN shares. Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a report on Thursday, January 22nd. Brookline Capital Management reiterated a “buy” rating on shares of Imunon in a research report on Wednesday, January 7th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Imunon stock. Riverview Capital Advisers LLC increased its holdings in Imunon, Inc. (NASDAQ:IMNN) by 193.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 34,364 shares of the company’s stock after acquiring an additional 22,649 shares during the period. Riverview Capital Advisers LLC owned about 1.41% of Imunon worth $176,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.47% of the company’s stock.

Imunon Stock Up 0.3%

Shares of NASDAQ IMNN opened at $3.32 on Friday. Imunon has a 12 month low of $2.99 and a 12 month high of $41.22. The company has a market cap of $10.19 million, a price-to-earnings ratio of -0.34 and a beta of 1.94. The business has a fifty day simple moving average of $3.74 and a 200-day simple moving average of $5.05.

Imunon (NASDAQ:IMNN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.73) by $0.57. As a group, sell-side analysts expect that Imunon will post -1.68 EPS for the current fiscal year.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.